ORLANDO — An inhaled insulin was noninferior to usual care for change in HbA1c and continuous glucose monitoring metrics among adults with type 1 diabetes, according to data from the INHALE-3 trial.
Technosphere insulin (Afrezza, MannKind Pharma) is a rapid-acting regular human insulin that is administered through an inhaler. The insulin was approved by the FDA in June 2014 for adults with type 1 and type 2 diabetes. New findings presented at the American Diabetes Association Scientific Sessions revealed the insulin provided similar glycemic benefits as usual care for adults with type 1